Ad
related to: difference between zarxio and neupogen- Biosciences Products
Learn more about our
biosimilar injectables
- Biosimilar Benefits
Learn about Biosimilars and
the future of accessible medicines
- Watch Videos
Hear from Amneal leaders
and tour manufacturing facilities
- Useful Resources
Download any of our
helpful resources
- Biosciences Products
Search results
Results from the WOW.Com Content Network
Filgrastim, sold under the brand name Neupogen among others, is a medication used to treat low neutrophil count. [21] Low neutrophil counts may occur with HIV/AIDS , following chemotherapy or radiation poisoning , or be of an unknown cause. [ 21 ]
On March 6, 2015, Zarxio obtained the first approval of FDA. [15] Sandoz's Zarxio is biosimilar to Amgen's Neupogen (filgrastim), which was originally licensed in 1991. This is the first product to be passed under the Biologics Price Competition and Innovation Act of 2009 (BPCI Act), which was passed as part of the Affordable Healthcare Act.
Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in people with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia; and to increase survival in people acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute ...
It's flu season right now, and the U.S. is in the midst of a wave that's straining hospitals. But not all influenza is the same. There are some notable differences between flu A and flu B strains ...
The sciatica study was smaller than the others, with about 100 people in the suzetrigine arm and in the placebo group, so there may not have been enough participants to show clear differences ...
For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...
The Food and Drugs Administration (FDA) first approved filgrastim on February 20, 1991 marketed by Amgen with the brand name Neupogen. [31] It was initially approved to reduce the risk of infection in patients with non-myeloid malignancies who are taking myelosuppressive anti-cancer drugs associated with febrile neutropenia with fever.
Flu A and flu B are the most common strains of the flu that circulate in humans. The U.S. is currently in the middle of flu season, with a high number of cases reported across the country. There ...
Ad
related to: difference between zarxio and neupogen